AnaptysBio, Inc. (ANAB) fair value analysis
Nasdaq · Updated 2026-10-19
ANAB price how computed
Valuation status
Awaiting full valuationANAB's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once ANAB's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $46.61
- Sector
- Healthcare
- 12-month range
- $22.06–$69.81
- Market cap
- $1.39B
- From 52-week high
- -33.2%
- Shares outstanding
- 29.9M
- Rank in Healthcare by quality score
- #162 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies for immune and inflammatory diseases. The company is headquartered in San Diego, California and operates in the United States biopharmaceutical industry.
ANAB currently ranks #162 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.39B
- P/E (trailing)
- 318x
- Revenue (TTM)
- $238M
- Net margin
- 82.4%
- EPS (TTM)
- $0.15
- Gross margin
- -90.8%
- Debt / equity
- 25.47
- Revenue growth (3-yr avg)
- 242.8%
- Shares outstanding
- 29.9M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $53.57
- 200-day average
- $49.52
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+76.1%)
2026-03 ▼ miss (-72.3%)
2025-12 ▲ beat (+69.9%)
2025-09 ▲ beat (+141.6%)
2025-06 ▲ beat (+15.2%)
2025-03 ▲ beat (+12.3%)
2024-12 ▲ beat (+57.8%)
2024-09 ▲ beat (+29.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 0 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $87.2
- Target vs last price
- +87.1%
What our data shows for ANAB
- Shares are trading in the middle of their 12-month price range of $22.06–$69.81.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ANAB's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ANAB news
TickrTrends' derived news-sentiment signal for ANAB is currently leaning positive, computed from recent coverage.
- AnaptysBio (ANAB) Shares Drop 8% Amid Delaware Breach of Contract Lawsuit Hearing (gurufocus.com, 2026-10-20)
- AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion for Jemperli (gurufocus.com, 2026-10-19)
- Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer (manilatimes.net, 2026-10-19)
More ANAB news
- AnaptysBio: Fully Valued; With Major Litigation Uncertainty (NASDAQ:ANAB) (seekingalpha.com, 2026-10-13)
- ANAB Maintained by JP Morgan -- Price Target Lowered to $60.00 (gurufocus.com, 2026-09-30)
- AnaptysBio Inc (ANAB) Q2 Revenue Beats Estimates; Price-to-Sales Ratio Signals High Growth Expectations (gurufocus.com, 2026-09-21)
What people are saying
Follow the ANAB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ANAB is a healthcare sector company with RSI zone momentum that shifted from oversold to neutral this week according to TickrTrends' derived indicators. The company's valuation verdict remains awaiting full valuation. The shift in RSI zone suggests reduced downward momentum compared to the previous week's reading.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — ANAB's quality grade declined from D to F this week, reflecting a deterioration in underlying business metrics tracked by TickrTrends. The stock's relative strength index zone shifted from neutral into oversold territory, indicating that selling pressure has intensified over the past seven days. The valuation verdict remains awaiting full valuation as of this reporting period.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ANAB stock undervalued?
ANAB's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is ANAB's TickrTrends verdict?
ANAB is currently marked 'Awaiting full valuation' - a verdict publishes automatically once ANAB's own trailing P/E history validates under our standards.
How does ANAB compare to other Healthcare stocks?
ANAB ranks #162 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ANAB overbought or oversold?
ANAB's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ANAB report earnings next?
ANAB's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does ANAB usually beat earnings estimates?
Over its last 8 reported quarters ANAB beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ANAB?
Of 10 analysts covering ANAB, 10 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $87.2 (+87.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.